Syndax Pharmaceuticals, Inc. (SNDX)

20.96 +0.16 (+0.77%) At close: 04:00PM EDT

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 184

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael A. Metzger M.B.A.	CEO & Director	1.1M	126.68k	1971
Dr. Neil Gallagher M.D., Ph.D.	President, Head of Research & Development	720.46k	N/A	1964
Mr. Keith Alan Goldan CPA	CFO, Treasurer & Chief Accounting Officer	674.65k	N/A	1971
Mr. Luke J. Albrecht	Senior VP, General Counsel & Secretary	631.36k	387.36k	1979
Dr. Catherine Madigan M.D.	Chief Medical Officer	655.84k	N/A	1972
Dr. Peter Ordentlich B.Sc., Ph.D.	Co-Founder & Chief Scientific Officer	N/A	N/A	1969
Dr. Richard A. Heyman Ph.D.	Co-Founder	N/A	N/A	1957
Dr. Ronald M. Evans Ph.D.	Co-Founder, Advisor and Chair of Scientific Advisory Board	N/A	N/A	1949
Dr. Michael Downes Ph.D.	Co-Founder	N/A	N/A	N/A
Sharon Klahre	Vice President of Investor Relations & Communications	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.